Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies☆ ☆This study was supported by NIH Grant R01 DK 36729 to GAG.
- 1 January 2003
- journal article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 30 (1), 90-96
- https://doi.org/10.1016/s1079-9796(03)00012-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryThe American Journal of Medicine, 2002
- Gaucher disease: perspectives on a prototype lysosomal diseaseCellular and Molecular Life Sciences, 2002
- The identification of eight novel glucocerebrosidase (GBA) mutations in patients with Gaucher diseaseHuman Mutation, 2002
- Mutation Prevalence among 51 Unrelated Spanish Patients with Gaucher Disease: Identification of 11 Novel MutationsBlood Cells, Molecules, and Diseases, 2001
- Glucocerebrosidase mutations among African-American patients with type 1 Gaucher diseaseAmerican Journal of Medical Genetics, 2001
- Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher DiseaseAmerican Journal of Human Genetics, 2000
- Glucocerebrosidase gene mutations in patients with type 2 Gaucher diseaseHuman Mutation, 2000
- 2 Gaucher's disease: molecular, genetic and enzymological aspectsBailliere's Clinical Haematology, 1997
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher's diseaseBiochemical and Biophysical Research Communications, 1965